Prevalence of cervical cancer in Ain Defla region (Algeria)

Aicha Laissaoui, Azdinia Zidane, Mohamed Amine Cherier, Mustapha Ould Khaoua, Rachida Allem

Abstract

The high rate of cervical cancer in Algeria and the absence of organized screening programs are well shown in this study, which aims to determine the prevalence of cervical cancer and describe the risk factors associated with this alarming prevalence. This retrospective study is based on data collected from medical records and A questionnaire was developed to assess the risk factors (such as: parity, age at first marriage, smoking, oral contraceptive, and Hormonal status) of cervical cancer among the participants. Face to Face interview were conducted with the participants. The result obtained from this study revealed that cervical cancer occupies the fourth place of cancer in the Wilaya of Ain Defla (4,71 %); the results confirm the effect of several risk factors such as early marriage age (below 20 years: 46.66 %), multiparity (53.33%), menopause (66.66 %); taking contraception (53.33%) and smoking in the development of this pathology. The adoption of an early and annual screening program in our region would be very important to us. In addition, the interest of annual screening is to raise women’s awareness of this pathology, particularly in isolated regions. (Afr J Reprod Health 2022; 26 [11]: 15-21).

The high rate of cervical cancer in Algeria and the absence of organized screening programs are well shown in this study, which aims to determine the prevalence of cervical cancer and describe the risk factors associated with this alarming prevalence. This retrospective study is based on data collected from medical records and A questionnaire was developed to assess the risk factors (such as: parity, age at first marriage, smoking, oral contraceptive, and Hormonal status) of cervical cancer among the participants. Face to Face interview were conducted with the participants. The result obtained from this study revealed that cervical cancer occupies the fourth place of cancer in the Wilaya of Ain Defla (4,71 %); the results confirm the effect of several risk factors such as early marriage age (below 20 years: 46.66 %), multiparity (53.33%), menopause (66.66 %); taking contraception (53.33%) and smoking in the development of this pathology. The adoption of an early and annual screening program in our region would be very important to us. In addition, the interest of annual screening is to raise women’s awareness of this pathology, particularly in isolated regions. (Afr J Reprod Health 2022; 26 [11]: 15-21).

Full Text:

PDF

References

Ngoma M and Autier P. Prévention du cancer: le cancer du col de l'utérus. Ecancer medical science 2019; 13.

Organisation mondiale de la santé. La lutte contre le cancer du col de lutérus: guide des pratiques essentielles 2017.

Baldauf JJ, Averous G, Baulon E, Thoma V, Talha-Vautravers A, Sananes N and Akladios Y.Neoplasias intraepiteliales del cuello uterino. EMC- Ginecol Obstet 2013; 49: 1-23.

Boublenza L, Moulessehoul S, Beldjillali H, Hadef K, Boulenouar F, Chabni N and Meguenni K. Analyse des activités de dépistage ducancer du col de lutérus dans une région de louest algérien entre 2007 et 2011. African Journal of Cancer 2013; 5 :11–15.

Pigneux I. Vingt ans de cancer du col en Aquitaine: épidémiologie et traitement. congrès de la société française d'oncologie gynécologique bordeaux, 17 novembre 2000: Spécial cancérologie. La Lettre du gynécologue 2001; 25-30.

El Gnaoui N, Saile R and Benomar H. Le frottis cervicovaginal un test incontournable dans le dépistage des lésions du col de l’utérus. Journal of Cancer Research and Clinical Oncology 2010; 2: 9-13.

Sawaya G F, Sung HY, Kearney, K.A, Miller M, Kinney W, Hiatt RA and Mandelblatt J. Advancing age and cervical cancer screening and prognosis. Journal of the American Geriatrics Society 2001; 49: 1499- 1504.

Fritih R, Yousfi Y, Asselah F, Maloum N and Hadj Hammou F. Cancer du col de l’utérus en Algérie. Annales de pathologie 2010; 30:123-5

Polman NJ, de Haan, Veldhuijzen NJ, Heideman DA de Ve HC, Meije CJ, Massuger L F, Kemenade F Jv and Berkhof J. Experience with hpv self-sampling and clinician-based sampling in women attending routine cervical screening in the netherlands. Preventive Medicine 2019; 125: 5– 11.

Nayar R and Wilbur D C. Le test de Papanicolaou et Bethesda 2014. Cancer Cytopathology 2015; 123:271-281.

Sahraoui S, Bouras N, Acharki A, Benider A, Tawfiq N, Jouhadi H and Kahlain A. Adénocarcinome du col utérin: étude rétrospectivede 83 cas. Gynécologie obstétrique et fertilité 2002; 30: 291-298.

Shrestha AD, Neupane D, Vedsted P and Kallestrup P. Prévalence, incidence et mortalité du cancer du col de l'utérus dans les pays à revenu faible et intermédiaire: une revue systématique. Asian Pacific journal of cancer prevention 2018; 319.

Hinkula M, Pukkala E, Kyyrönen P, Laukkanen P, Koskela P, Paavonen J, Lehtinen M and Kauppila A. A population-based study on the risk of cervical cancer and cervical intraepithelial neoplasia among grand multiparous women in finland. British Journal of Cancer 2004; 90 :1025- 1029.

Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, Smith JS Shah K V , Meijer C J L M and Bosch F X .Role of parity and human papillomavirus in cervical cancer: the iarc multicentriccase-control study. The Lancet 359: 2002 .1093–1101.

Arfailasufandi R, Mudigdo A and Sudiyanto A. The effect of obesity, oral contraceptive and passive smoking on the risk of cervical cancer. Journal of Epidemiology and Public Health 2019;4 :189–197.

Mubiayi N, Bogaert E, Boman F, Leblanc E, Vinatier D, Leroy J and Querleu D. Histoire du suivi cytologique de 148 femmes atteintes d'un cancer invasif du col utérin. Gynécologie obstétrique et fertilité 2002; 30: 210-217.

Ben Youssef R, Maalej M, Ben Youssef L, Ben Abdallah M and Rahal K. Le cancer du col utérin en tunisie. présentation clinique et évolution au cours d’une période de 10 ans. Journal de Gynécologie Obstétrique et Biologie 1987;16 :63–67.

Bannour N, Boughizane S, Naifer R, Slama O, Trabelsi A, Bibi M, Zheni S, Ben Abdallah M, H Khairi H and Bouaouina N. Le cancer invasif du col utérin dans le centre tunisien. approches épidémiologique, clinique et thérapeutique. étude rétrospective de 96 cas. Oncologie 2004;6 :481–488.

Yokoyama Y, Takachi R, Ishihara J, Ishii Y, Sasazuki S, Sawada N Shinozawa Y, Tanaka J , Kato E, Kitamura K, Nakamura K and Tsugane Sh.Validity of short and long self-administered food frequency questionnaires in ranking dietary intake in middle-aged and elderly japanese in the japan public health center-based prospective study for the next generation (jphc-next) protocol area. Journal of epidemiology 2016; JE20150064.

Smith J. International agency for research on cancer (iarc) multicentric cervical cancer study group. herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. Journal of the National Cancer Institute 2002; 94 :1604–1613.

Ardahan M. Incidence, facteurs de risque, critères de diagnostic et méthodes de préventiondu cancer du col de l'utérus. Progrès récents dans le cancer du col de l'utérus; Départementdes soins infirmiers de santé publique, Université Ege: Polnova, Turquie 2016; 2-31.

Trimble CL, Genkinger JM, Burke AE, Hoffman SC, Helzlsouer KJ, Diener-West M, Comstock GW and Alberg AJ. Le tabagisme actif et passif et le risque de néoplasie cervicale. obstetrics and gynecology 2005; 105, 174.

Ono A, Nakagawa M, Ikuta E, WatanabeY and Koshiyama M. Relationship between tobacco smoking and cervical cancer. Women's Health – Open Journal 2019; 5: 19–21.

de Witte L, Nabatov A, Pion , Fluitsma D, De Jong M, de Gruijl T Piguet V, van Kooyk Y and Teunis Geijtenbeek TBH. Langerin is anatural barrier to hiv-1 transmission by langerhans cells. Nature medicine 2007 ;13: 367– 371.

Feng Y, Zou W, Hu C, Li G, Zhou S, HeY Ma F, Deng CH and Sun L. Modulation of casc2/mir-21/pten pathway sensitizes cervical cancer to cisplatin. Archives of biochemistry and biophysics 2017; 623: 20–30.

Alam S, Conway MJ, Chen HS and Meyers C. The cigarette smoke carcinogen benzo [a] pyrene enhances human papillomavirus synthesis. Journal of Virology 2008; 82, 1053–1058

Refbacks

  • There are currently no refbacks.